Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804689 | 1.00 | POLB (0.43) | POLBTRPV1SYKNPC1RAB9A | |
| SCHEMBL14195878 | 0.93 | POLB (0.42) | POLBTRPV1SYKNPC1RAB9A | |
| SCHEMBL14195874 | 0.89 | POLB (0.44) | POLBTRPV1SYKNPC1RAB9A | |
| SCHEMBL4875793 | 0.81 | ELANE (0.41) | SYKNPC1RAB9ATOP2ATOP2B | |
| SCHEMBL2209322 | 0.80 | NPC1 (0.40) | SYKNPC1RAB9ATOP2ATOP2B | |
| SCHEMBL2209326 | 0.80 | NPC1 (0.40) | SYKNPC1RAB9ATOP2ATOP2B | |
| SCHEMBL4393129 | 0.79 | POLB (0.47) | POLBTRPV1NPC1RAB9ANAMPT | |
| SCHEMBL4387066 | 0.79 | POLB (0.47) | POLBTRPV1NPC1RAB9ANAMPT | |
| SCHEMBL4393130 | 0.79 | POLB (0.47) | POLBTRPV1NPC1RAB9ANAMPT | |
| SCHEMBL4394884 | 0.79 | POLB (0.47) | POLBTRPV1NPC1RAB9ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361766-B2 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2006076569-A2 | BICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| US-20060154956-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154956-A1 | Bicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, CCKBR | POLB 3169/4885TRPV1 139/4885SYK 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.